

Luton & Dunstable University Hospital
Bedfordshire Hospitals NHS Foundation Trust
Lewsey Road
Luton
LU4 0DZ

Bedford Hospital
Bedfordshire Hospitals NHS Foundation Trust
Kempston Road
Bedford
MK42 9DJ

23/10/2020

Dear Requester,

Thank you for your Freedom of Information request which was received within the Trust.

In accordance with S.1 (1) (a) of the Freedom of Information Act 2000 (FOIA), I can confirm that we do hold the information relevant to your request. FOI 158

Luton and Dunstable University Hospitals Response

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- Atezolizumab: **1**
- Carboplatin with Gemcitabine: **0**
- Carboplatin with Paclitaxel: **0**
- Carboplatin single or in any other combination: **0**
- Cisplatin with Gemcitabine: **5**
- Cisplatin single or in any other combination: **0**
- Nivolumab: **0**
- MVAC with G-CSF: **0**
- Pembrolizumab: **1**
- Any other regimen including Paclitaxel: **0**
- Any other chemo regimen: **0**

- Other active systemic anti-cancer therapy [please state]: 0
- Palliative care only: unable to establish from pharmacy data

Q2. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib: 0
- Alectinib: 2
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel: 0
- Atezolizumab monotherapy: 1
- Bevacizumab: 0
- Brigatinib: 0
- Ceritinib: 0
- Crizotinib: 1
- Dacomitinib: 0
- Docetaxel monotherapy: 0
- Durvalumab: 0
- Erlotinib: 5
- Gefitinib: 0
- Gemcitabine: 2 (in combination with carboplatin)
- Nectinib: 0
- Nintedanib with Docetaxel: 0
- Nivolumab: 0
- Osimertinib: 1
- Paclitaxel: 0
- Pembrolizumab chemo in combination: 0
- Pembrolizumab monotherapy: 5
- Pemetrexed: 2
- Pemetrexed with Carboplatin: 3
- Pemetrexed with Cisplatin: 0
- Ramucirumab: 0
- Vinorelbine and cisplatin/carboplatin: 2

Q3. Could you please provide the total number of patients with any treatment in the last three months for:

- Total non-small cell lung cancer (NSCLC): **24**
- Squamous non-small cell lung cancer (Sq NSCLC): **2**
- Non-squamous non-small cell lung cancer (Non-Sq NSCLC): **22**

Bedford Hospitals Response

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- Atezolizumab = **0**
- Carboplatin with Gemcitabine = **2**
- Carboplatin with Paclitaxel = **0**
- Carboplatin single or in any other combination = **0**
- Cisplatin with Gemcitabine = **2**
- Cisplatin single or in any other combination = **0**
- Nivolumab = **0**
- MVAC with G-CSF = **0**
- Pembrolizumab = **2**
- Any other regimen including Paclitaxel = **0**
- Any other chemo regimen = **0**
- Other active systemic anti-cancer therapy [please state] = **0**
- Palliative care only **0**

Q2. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib = **4**
- Alectinib = **1**
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel = **0**
- Atezolizumab monotherapy = **3**
- Bevacizumab = **0**
- Brigatinib = **0**
- Ceritinib = **0**
- Crizotinib = **1**
- Dacomitinib = **0**
- Docetaxel monotherapy = **0**
- Durvalumab = **2**
- Erlotinib = **0**
- Gefitinib = **0**
- Gemcitabine = **0**
- Necitumumab = **0**
- Nintedanib with Docetaxel = **0**
- Nivolumab = **0**
- Osimertinib = **1**
- Paclitaxel = **2**
- Pembrolizumab chemo in combination = **7**
- Pembrolizumab monotherapy = **17**

- Pemetrexed = 0
- Pemetrexed with Carboplatin = 0
- Pemetrexed with Cisplatin = 0
- Ramucirumab = 0
- Vinorelbine and cisplatin/carboplatin = 15

Q3. Could you please provide the total number of patients with any treatment in the last three months for:

- Total non-small cell lung cancer (NSCLC) = 51 (Only Systemic Anti-Cancer Therapy patients)
- Squamous non-small cell lung cancer (Sq NSCLC) = 13 (Only Systemic Anti-Cancer Therapy patients)
- Non-squamous non-small cell lung cancer (Non-Sq NSCLC) = 38 (Only Systemic Anti-Cancer Therapy patients)

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to:

Luton & Dunstable University Hospital
 Bedfordshire Hospitals NHS Foundation Trust
 Lewsey Road
 Luton
 LU4 0DZ

Bedford Hospital
 Bedfordshire Hospitals NHS Foundation Trust
 Kempston Road
 Bedford
 MK42 9DJ

Or by emailing bhn-tr.foibedfordshirehospitals@nhs.net. This option is available to you for up to three calendar months from the date your response was issued.

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF
www.ico.org.uk

Yours sincerely,

IG/FOI Coordinator

Bedford Hospital, Kempston, Bedford
MK42 9DJ

Luton & Dunstable Hospital
Lewsey Road, Luton
LU4 0DZ